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Background: The identification of potential tumor markers can improve therapeutic planning and patient management.
The aim of this study was to highlight the significance of IL-6 in esophageal squamous cell carcinoma (SCC).
Methods: We retrospectively analyzed the clinical outcomes of 173 patients with esophageal SCC, and examined the
correlation between IL-6 levels and clinical outcomes in esophageal cancer patients. Furthermore, the human
esophageal SCC cell line CE81T was selected for cellular and animal experiments to investigate changes in tumor
behavior and treatment response after manipulation of IL-6 expression.
Results: In clinical outcome analysis, positive IL-6 staining and poor treatment response was significantly associated
with shorter survival. Furthermore, the frequency of IL-6 immunoreactivity was significantly higher in esophageal
cancer specimens than in non-malignant epithelium, and this staining was positively linked to the development of
distant metastasis (p = 0.0003) and lower treatment response rates (p = 0.0001).By ELISA analysis, IL-6 serum levels were
significantly elevated in patients developing disease failure.When IL-6 expression was inhibited, aggressive tumor
behavior and radiation resistance could be overcome in vitro and in vivo. The underlying changes included increased
cell death, less epithelial-mesenchymal transition and attenuated STAT3 activation. IL-6 inhibition was also associated
with attenuated angiogenesis in tumor-bearing mice.
Conclusions: IL-6 was significantly associated with poor prognosis in patients with esophageal cancer. Targeting this
cytokine could be a promising strategy for treatment of esophageal cancer, as evidenced by inhibition of aggressive
tumor behavior and treatment resistance.
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Esophageal cancer, an aggressive upper gastrointestinal
malignancy, generally presents as a locally advanced
disease and requires a multimodal concept. Despite
improvements in its detection and management, the
prognosis in patients with esophageal cancer remains
poor, with a 5-year survival of 15–34% [1,2]. Most patients
who undergo curative treatment for esophageal cancer
will eventually relapse and die as a result of their disease.
Neoadjuvant chemoradiotherapy (CCRT) can increase the* Correspondence: miaofen@adm.cgmh.org.tw
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reproduction in any medium, provided the orchance of R0 resection, and responders will have a survival
benefit [3]. Patient selection is important to guide
multidisciplinary therapy. The identification of potential
molecular markers to predict response to CCRT and
recurrence is important for the effective management and
prognosis of esophageal cancer.
Proinflammatory cytokine may contribute to tumor
progression by stimulating angiogenesis, invasion and
metastasis [4,5] IL-6 is a pleiotropic cytokine that is
capable of modulating diverse cell functions such as
inflammatory reactions, and is a major activator of the
JAK/STAT3 and PI3K/AKT signaling pathways [6]. IL-6
signaling has been implicated in the regulation of tumor
growth and metastatic spread in different cancers [7-9].
Moreover, increased IL-6 serum levels were reported totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prostate, ovarian and gastrointestinal cancers [10-12].
Although evidence suggests that IL-6 is a critical factor in
a variety of malignancies [11,13,14], how IL-6 modulates
the biological activities of esophageal carcinoma cells and
how it is associated with the prognosis of esophageal
cancer remains unclear. There are two distinct histological
types of esophageal cancer: squamous cell carcinoma
(SCC) and adenocarcinoma. There are marked differences
between these carcinomas in incidence, natural history
and treatment outcomes [15]. The majority of esophageal
SCC cases occur in Asia, with the predominant type in
Taiwan being SCC [16]. We therefore investigated the
role of IL-6 in esophageal SCC in vitro and in vivo, and
examined the correlation between IL-6 levels and clinical
outcomes in esophageal cancer patients.
Materials and methods
Patient characteristics
The Institutional Review Board of Chang Gung Memorial
Hospital approved the present study (Permit Number:
96-1693B). The written consents were signed by the








Figure 1 IL-6 levels in esophageal SCC. a. Representative IHC staining w
non-malignant epithelium from TMA blocks. b. IHC staining with an anti-IL
representative slides are shown at magnifications of × 100 (left panel) and ×
anti-IL-6R antibody of esophageal cancer and adjacent non-malignant epitin the hospital and used for research. Patients who did not
comply with the treatment regimen and those who
received surgery alone for early-stage esophageal cancer
were excluded from the study. A total of 173 patients
with esophageal SCC who completed curative treatment
were enrolled in the study. The curative treatment for
esophageal cancer included neoadjuvant CCRT combined
with surgery or definitive CCRT according to the
guidelines proposed by oncology team at our hospital.
On completion of neoadjuvant CCRT, patients underwent
a repeat CT scan and endoscopic examination to
determine the response to treatment. If the tumor was
considered resectable, patients underwent surgery for the
residual tumor. Pathologic complete response (CR) was
defined as absence of residual invasive tumor in the
surgical specimen in patients undergoing surgical inter-
vention. For patients who refused surgery or in whom it
was contraindicated, a second round of CCRT was
administered, comprising two courses of chemotherapy
and radiotherapy of a total of 60–63 Gy. Specimens col-
lected from the 173 patients at diagnosis were subjected
to immunochemical analysis. The main end points were







ith an anti-IL-6 antibody of esophageal cancer and adjacent
-6 antibody of human esophageal cancer specimens. Images of
200 (right panel). c. Representative images of IHC staining with an
helium from TMA blocks.
Table 1 Clinico-pathological characteristics of esophageal
cancer patients for immunohistochemical investigation
No. of patients
IHC-IL-6(-) IHC- IL-6 (+) p value
patients 85 88
Age
> = 56y/0 43 44 0.938
<56y/o 42 44
Location
Upper third 22 26 0.498
Middle third 48 42










Response to Neoadjuvant Tx 0.0001*
Response 69 47
Non- response 16 41











Abbreviations: Neoadjuvant Tx = neoadjuvant chemoradiotherapy.
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was analyzed statistically using the Kaplan–Meier
method. The significance of between-group differences
was assessed using the log-rank test. Multivariate analyses
were performed using a Cox regression model for survival.
Immunohistochemical staining (IHC)
Formalin-fixed, paraffin-embedded tissues from 173
patients with esophageal cancer were subjected to IHC
staining. Dissected esophageal cancer specimens from 20
of these patients were converted into tissue microarray
(TMA) blocks using an AutoTiss 1000 arrayer (Ever Bio-
Technology, Canada). The TMA block contained esopha-
geal SCCs and the adjacent non-malignant epithelium.
The quality of the TMA slides was confirmed by the path-
ologist using hematoxylin- and eosin-stained slides. The
IHC data for the specimens were assessed using the semi-
quantitative immunoreactive score (IRS). The criterion for
positive staining was an IRS score of ≥2. The details were
described in Additional file 1: Supplementary methods.
Cell culture and reagents
The human esophageal cancer cell line CE81T, derived
from a well-differentiated esophageal SCC, was obtained
from the Bioresource Collection and Research Center
(BCRC),and cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum.
The IL-6-neutralizing antibody, STAT3 siRNA and the
JAK inhibitor AG490 were purchased from R&D Systems
(Minneapolis, MN) and Sigma (St. Louis, MO), respectively.
The IL-6-GFP silencing vector (human IL6 shRNA
constructs in retroviral GFP vector) and GFP-control
vector (Non-effective scrambled shRNA cassette in
retroviral GFP vector) were purchased from Origene
Technologies, Inc. (Rockville, MD). Transfection in CE81T
was carried out by Lipofectamine™ 2000 (Invitrogen)
according to the manufacturer’s instructions. Stable cancer
cells were generated by transfecting CE81T cells with
either the IL-6 silencing vectors or control vectors,
followed by selection with puromycin for 4 weeks.
Cell growth
To measure cell growth, 1×104 cells per well were plated
into 6-well dishes. At the indicated time-points, cells were
trypsinized, collected and surviving cells counted using
Trypan blue exclusion, from which the survival curves for
CE81T transfectants ( wild type, with control vectors, and
with IL-6 silencing vectors) were established.
Immunoblotting
To determine the in vitro effects of STAT3 siRNA,
proteins were extracted from cells transfected with
STAT3 siRNA for 72 h. To determine the in vitro effects
of the JAK inhibitor and the anti-IL-6 antibody, proteinswere extracted from cells incubated in the presence of
50 μM AG490 or 5 μg/ml IL-6 neutralizing antibodies
for 24 h. The details were described in Additional file 1:
Supplementary methods.
Immunofluorescence staining (IF) and Statistical analysis
The details were described in Additional file 1:
Supplementary methods.
Enzyme-linked immunosorbent assay (ELISA) analysis of
IL-6 level
We examined the serum level of IL-6 from 71 patients
among subjects enrolled with esophageal cancer in the
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peripheral blood were drawn from each patient. More-
over, IL-6 levels in cellular supertnant and murine serum
were tested. Levels of IL-6 in samples were analyzed
using an IL-6 Quantikine ELISA Kit (R&D system). The
details were described in Additional file 1: Supplementary
methods.
Tumor xenografts
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals as promulgated by the Institutes of
Laboratory Animal Resources, National Research Council,
U.S.A. The protocol was approved by the Committee
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Figure 2 Role of IL-6 in tumor growth. a. Effect of an IL-6-GFP silencing
immunofluorescence and immunoblotting. The results of representative sli
with control-GFP vector significantly reduced IL-6 levels. b. Effect of IL-6 on
counting. The same number of cells (104) were plated in each plate on day
number of viable cells after incubation for 2, 4 and 6 days. The Y axis repre
experiments; bars, SD. *, p < 0.05. c. Effect of IL-6 inhibition on tumor xenog
experiments. *, p < 0.05. IL-6 expression was also evaluated by IHC staining
inhibition on cell death, as assessed by FACS and immunofluorescence staMemorial Hospital (Permit Number: 2012080903).
Eight-week-old male athymic nude mice were used
and all animal experiments conformed to the protocols
approved by the experimental animal committee of
our hospital. CE81T cancer cell transfectants (1 × 106
per implantation, five animals per group) were
subcutaneously implanted in the dorsal gluteal region.
To determine in vivo radiosensitivity, local irradiation
(15 Gy) was performed when the tumor volume
reached 500 mm3. Radiosensitivity was indicated by a
growth delay (i.e., the time required for the tumor to
recover its previous volume after irradiation). Duplicate
experiments were performed for growth delay ana-
lyses. The details were described in Additional file 1:
Supplementary methods.CE81T 
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vector on the level of IL-6 in CE81T, as assessed by
des are shown. The IL-6-GFP silencing vector as compared with that
the proliferation of CE81T cancer cells as determined by viable cell
0 and allowed to grow in their respective cultures. We counted the
sents the viable cell number. Point, means of three separate
raft growth. Data represent the means ± SD of three independent
of xenografts. Representative slides are shown. d. Effect of IL-6
ining. The results of representative slides are shown.
Figure 3 Role of IL-6 in aggressive tumor behavior and EMT changes. a. Effect of IL-6 inhibition on the migration ability of esophageal
cancer cells. Plates were photographed at the times indicated. Representative slides and quantitative data (y-axis shows the relative ratio,
normalized to the distance under control conditions) are shown. b. Effect of IL-6 inhibition on EMT-associated proteins. The changes of E-
cadherin and vimentin expression were evaluated by immunofluorescence, and the results of representative slides are shown. In addition,
changes in the levels of EMT-associated proteins were evaluated by immunoblotting (W, wild-type cells; V, cells transfected with the control
vector; IL-6-, cells transfected with the IL-6 silencing vector). c. Representative IHC staining with an anti-p-STAT3 antibody in esophageal cancer
and adjacent non-malignant epithelium on slides from TMA blocks. d. P-STAT3 levels correlate positively with IL-6 levels in human esophageal
cancer specimens (p < 0.001). Representative images of positive IL-6 and p-STAT3 staining on slides from a selected tumor specimen, and
representative negative staining for IL-6 and p-STAT3 on slides from another tumor specimen, are shown. e. Effect of the IL-6 silencing vector on
STAT3 activation, as examined by immunofluorescence analysis. f. Effect of inhibited IL-6 signaling on STAT3 activation and EMT-related protein
levels, as determined by immunoblotting (W, proteins were extracted from cells under control condition; IL-6Ab, proteins were extracted from
cells incubated in the presence of 5 μg/ml IL-6 neutralizing antibodies for 24 h; AG, proteins were extracted from cells incubated in the presence
of 50 μM AG490 for 24 h; SI, proteins were extracted from cells 72 h after transfection with STAT3 siRNA).
Chen et al. Molecular Cancer 2013, 12:26 Page 5 of 12
http://www.molecular-cancer.com/content/12/1/26
Chen et al. Molecular Cancer 2013, 12:26 Page 6 of 12
http://www.molecular-cancer.com/content/12/1/26Results
Level of IL-6 in esophageal SCC
The IHC data for TMA slides demonstrated that IL-6
was overexpressed in tumor tissues compared to adja-
cent non-malignant epithelial tissues (Figure 1a).
Figure 1b showed the representative slides of positive
staining and negative staining with anti-IL-6 antibody
for human esophageal cancer specimens. Of the 173
esophageal cancer tissues, 88 (51%) showed positive
IL-6 immunoreactivity (41% (45/109) in ≤ T3 versus
67% (43/64) in T4, P = 0.001). Furthermore, there was
a positive correlation between IL-6 overexpression
and cancers developing loco-regional failure or distant
metastasis (Table 1). The biological activities of IL-6 are
mediated through binding to a membrane-bound or
soluble form of IL-6 receptor. By IHC analysis of TMA
slides, IL-6 receptor (IL-6R) was expressed in both tumor
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Figure 4 Effects of circulating IL-6 on tumor aggressiveness. a. The lev
or without IL-6 silencing vectors were examined by ELISA. Columns, means
patients were examined by ELISA analysis. Columns are the means of spec
DM = distant metastasis). c. IHC using MMP-9, E-cadherin, CD31, and VEGF
were significantly reduced by the angiogenesis and EMT-related changes a
normalized by the value of target protein in tumor transfected with contro
P < 0.05 (C-V, cells transfected with the control vector; IL-6 SV, cells transfecRole of IL-6 in tumor growth
As demonstrated in Figure 2a, the IL-6 silencing vector
significantly inhibited IL-6 expression in CE81T cells. By
viable cell counting over 6 days and observation of
xenograft tumors, the IL-6 silencing vector significantly
inhibited tumor growth in vitro (Figure 2b) and in vivo
(Figure 2c). Figure 2d showed that the cell death rate
increased from 5.6 ± 1.2% to 13.5 ± 1.8% in CE81T
cells after treatment with an IL-6-neutralizing antibody
(as measured by flow cytometry) and by the IL-6 silencing
vector (propidium iodide staining).Role of IL-6 in tumor invasion and underlying
mechanisms
There was a positive link between IL-6 and tumor stage
and disease failure in patients with esophageal cancer
(Table 1). Furthermore, as demonstrated using migration
































LR(-) LR(+) DM(-) DM(+)
120
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els of IL-6 in cell supernatant and serum of mice bearing tumors with
of 3 separate experiments; bars, SD. *, P < 0.05. b. Serum IL-6 levels of
imen; Bars, SD; *, P < 0.05. (LR = Local-regional Recurrence /persistent;
staining in tumors 20 days after implantation. IL-6 silencing vectors
s compared with control-GFP vector. The Y-axis represents the ratio
l vectors. Columns, means of 3 separate experiments; bars, SD. *,
ted with the IL-6 silencing vector).
Table 2 Significance of IL-6 expression stratified according
to the occurrence of local- regional failure (LR) or distant
metastasis (DM) in 71 patients
IL-6 serum level
<mean > =mean
LR + 12 32 P = 0.001
− 18 9
DM + 10 24 P = 0.035
− 20 17
LR = Local-regional Recurrence /persistent; DM = distant metastasis.
Table 3 Significance of IL-6 expression stratified
according to the complete response to neoadjuvant
treatment in 55 patients with surgery resection
IL-6
+ −
Pathologic CR + 3 11 P = 0.052
− 21 20
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Epithelial-mesenchymal transition (EMT) is a key event in
invasiveness [17]. As shown in Figure 3b, the IL-6
silencing vector reversed EMT changes, with increased
E-cadherin expressions, and decreased matrix metallo-
proteinase (MMP)-9, vimentin and Snail, a repressor of
E-cadherin expression. The activation of STAT3 signaling
was reported to play important roles in the induction of
aggressive tumor behavior and EMT changes in cancer
[18], including cancers in the upper aerodigestive tract
[8,19]. As shown in Table 1 and Figure 3c–d, positive
staining for p-STAT3 was evident in 47% of the 173
cancer specimens, and a significant positive correlation
was found in cancer specimen that expressed IL-6 and
p-STAT3. As determined by immunofluorescence and
immunoblotting analysis (Figure 3e-f ), IL-6 inhibition
significantly attenuated the activation of STAT3 in vitro.
Moreover, when STAT3 signaling was inhibited by STAT3
siRNA or the JAK inhibitor AG490, the decreases in
EMT- related protein levels were comparable to those
induced by the IL-6-neutralizing antibody (Figure 3f).
Therefore, it appears that altered STAT3 activation
and subsequent EMT might, at least in part, be respon-
sible for the aggressive tumor behavior in IL-6-positive
esophageal cancer.
Effects of circulating IL-6 on tumor aggressiveness
We used ELISA assay to test the level of IL-6 in the
supernatant of cell culture and the serum of mice bearing
tumors. As shown in Figure 4a, IL-6 silencing vector
clearly attenuated IL-6 secretion. Moreover, the serum
levels of IL-6 were examined by ELISA. The mean IL-6
levels in serum samples from 71 patients with esophageal
cancer were 39 ± 7.7 pg/mL. Serum IL-6 levels were
significantly elevated in patients with local-regional failure
or developing distant metastasis compared to those in
patients with disease control (Figure 4b). Table 2 also
showed that IL-6 serum levels were significantly correlated
with a greater probability of developing local-regional
failure and distant metastasis. In addition to EMT,
angiogenesis is one of the mechanisms that promote tumor
progression. The most prominent and best-characterized
pro-angiogenic pathway is vascular endothelial growth
factor (VEGF) signaling [20], and CD31-mediated
endothelial cell-cell interactions are involved in angiogenesis
[21]. Therefore, the vascular network within the tumor
was measured by VEGF staining and microvascular
density (MVD) analysis after CD31 staining. When esopha-
geal cancer cells with control vectors and those with IL-6
silencing vectors were subcutaneously implanted into
mice, we found that the growth inhibiting effect induced
by IL-6 silencing vector associated with lower expression
levels of EMT- and angiogenesis-related factor (Figure 4c).
Accordingly, we suggested that circulating IL-6 plays arole in tumor promotion, and the induction of angiogen-
esis and EMT might be the underling mechanisms.
IL-6 correlates with treatment response in esophageal SCC
Regarding clinical data, the expression of IL-6 was
significantly associated with a lower rate of response to
curative treatment in the 173 esophageal SCC patients
(Table 1), and a lower pathological complete response rate
in the 55 patients who underwent surgical intervention
(Table 3). Therefore, we investigated the role of IL-6 in
treatment resistance and the underlying mechanisms.
Colony-forming assay data (Figure 5a) and the in vivo
delay in tumor growth (Figure 5b) demonstrated that the
IL-6 silencing vector significantly sensitized esophageal
cancer cells to irradiation. As shown in Figure 5c-d,
inhibition of IL-6 increased cell death and DNA damage
and attenuated STAT3 activation after irradiation.
Tumor vascularity have been shown to be linked to the
tumor-bed effect induced by irradiation [22]. To investigate
whether angiogenesis underlies radiation resistance
triggered by IL-6, the vascular network within the tumor
by MVD analysis and the expression of VEGF after
irradiation were measured. As shown in Figure 5d, the
IL-6 silencing vector significantly decreased angiogenesis
by evidence of decreased MVD and VEGF staining in
irradiated tumors.
Correlation between the IL-6 level and clinical outcome
As shown in Figure 6, IL-6 is a significant predictor for
OS. The median OS times were 16 and 42 months in
patients who completed CCRT treatment and those who
underwent surgical intervention, respectively. In addition,
Tables 1, 2, 3 showed that IL-6 was significantly correlated
Figure 5 Effects of IL-6 on radiation responses. a. Cells were irradiated with 0, 2, 4, 6, and 8 Gy, and survival curves were constructed using
colony-forming assay data. Data represent the means of three experiments. *, p < 0.05. IL-6 silencing vectors significantly sensitized tumor cells to
irradiation. b. Effects of IL-6 on in vivo radiosensitivity, as assessed by evaluation of tumor growth following irradiation (15 Gy). The y-axis shows
the tumor volume ratio at each time point, divided by the tumor volume at irradiation. (C-V, cells transfected with the control vector; IL-6 SV, cells
transfected with the IL-6 silencing vector). c. The in vitro effects of IL-6 inhibition on p-STAT3 and p-H2AX levels and cell death, as evaluated by
IHC staining and Annexin V-PI staining in irradiated cells. d. An IL-6-silencing vector decreased angiogenesis in tumors, as evaluated by
immunoblotting and IHC analysis of tumor specimens 14 days after local irradiation. Representative slides are shown. The Y axis represents the
ratio normalized by the value of target protein in tumor transfected with control vectors. Columns, means of 3 separate experiments; bars, SD. *,
P < 0.05. (C-V, cells transfected with the control vector; IL-6 SV, cells transfected with the IL-6 silencing vector).
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and a higher recurrence rate after curative treatment.
In univariate and multivariate analyses, poor treatment
response, no tumor resection, and positive IL-6 staining
were significantly associated with shorter survival
(Tables 4, 5, 6). Furthermore, in the subgroup of 118
patients treated with CCRT, but not in the 55 who
underwent surgical intervention, positive IL-6 staining
retained predictive power concerning survival in a
multivariate analysis (Tables 7, 8).
Discussion
Understanding the molecular mechanisms underlying
aggressive tumor growth in esophageal SCC is pivotal to
identifying novel targets for pharmacological intervention.
Furthermore, clinical data [2,3,23] suggest the need for
markers that predict responses to neoadjuvant CCRT and
help to identify patients at high risk of tumor recurrence
and distant metastasis. However, no suitable markers have
been identified to date. The inflammatory cytokine IL-6
contributes to the growth and progression of various
malignancies, such as HNSCC, prostate cancer and
gastrointestinal cancer, and acts as an autocrine growth
factor and an anti-apoptotic factor for various stimuli,
including anticancer agents [11,24-27]. Moreover, the IL-6
/STAT3 pathway is important for the development of
inflammation-associated intestinal tumorigenesis. SimilarFigure 6 Correlation between IL-6 level and clinical outcome. Survival
(b) patients treated with CCRT and (c) patients who underwent pre-operat
than the IL-6-negative group.to other series [11,28], we found that IL-6 and IL-6R were
detected in both esophageal cancer specimens and
esophageal carcinoma cell lines. IL-6 expression was
higher in esophageal cancer specimens compared with
non-malignant tissues. Furthermore, positive staining for
IL-6 was associated with higher tumor stage, higher rates
of tumor recurrence and distant metastasis. To further
investigate whether IL-6 was responsible for aggressive
tumor growth in esophageal SCC, we suppressed IL-6 in
esophageal cancer cells using a silencing vector. Data
obtained from cell and xenograft tumor growth
experiments revealed that inhibiting IL-6 resulted in
slower tumor growth and reduced invasiveness. The
transformation of an epithelial cell into a mesenchymal
cell appears to be functionally relevant to the invasive
characteristics of epithelial tumors, including esophageal
cancer [19,29,30]. At the molecular marker level, EMT is
characterized by the loss of E-cadherin and increased
expression of invasion-related factors [31]. In cell
experiments, the IL-6 silencing vector induced both an
increase in E-cadherin levels in esophageal cancer cells,
and decreases in MMP-9 levels. Constitutive activation
of STAT3 signaling has been reported to contribute to
oncogenesis by promoting proliferation and EMT, and
IL-6 is a major activator of JAK/STAT3 signaling
[8,32-34]. Therefore, we examined the links between
STAT3 activation, IL-6 and EMT. When blocking STAT3differences according to IL-6 positivity for (a) all 173 patients,
ive CCRT and surgery. The IL-6-positive group exhibited shorter survival
Table 4 Univariate analysis to determine factors
associated with prognosis




Clinical stage 0.271 0.006*
Tumor resection 0.001* 0.000*
Positive staining for IL-6 0.000* 0.000*
Positive staining for p-STAT3 0.000* 0.000*
Local-regional Recurrence 0.002* 0.000*
Distant metastasis 0.03* 0.000*
Treatment response 0.000* 0.000*
Table 6 Multivariate analysis to determine molecular
markers associated with prognosis (DFS) of patients
Variables Odd ratios 95% confidence interval p
IL-6 staining 5.424 3.349-8.784 <0.001*
p-STAT3 staining 0.724 0.465-1.128 0.153
Tumor resection 0.365 0.241-0.553 <0.001*
Clinical stage 1.655 1.058-2.589 0.027*
Treatment response 3.719 2.135-4.733 <0.001*
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decreases in EMT-related protein levels were comparable
to those induced by IL-6 silencing vector. Furthermore,
IHC data obtained from clinical samples demonstrated
that IL-6 expression was significantly correlated with
p-STAT3 staining. Therefore, it is likely that STAT3
activation plays a role in transmitting IL-6 signals to
downstream targets that regulate EMTand invasiveness.
In the present study, IL-6 silencing vectors significantly
decreased IL-6 levels seen in the supernatant of cell
culture medium and the serum of mice bearing tumors.
Moreover, in the clinic, IL-6 serum levels seem to be
elevated in a subgroup of patients with local-regional
failure or distant metastasis. We assume that circulating
IL-6 plays an important role to stimulate tumor
growth in vivo, besides direct action on malignant
cells. Angiogenesis is one of the mechanisms that
promote tumor progression, and CD31-mediated
endothelial cell-cell interactions are involved in angio-
genesis. Moreover, STAT3 activation has been reported
to modulate the expression of genes that mediate
angiogenesis; e.g., VEGF [35]. Accordingly, the links
between IL-6, angiogenesis, and promotion of cancer
in tumor-bearing mice were further investigated using
a xenograft tumor model. Our data from animal
experiments demonstrated that IL-6 level positively linked
with angiogenesis in addition to EMT. These findings
indicated that the promotion of EMT changes andTable 5 Multivariate analysis to determine molecular






IL-6 staining 5.319 2.906-9.734 <0.001*
p-STAT3 staining 0.926 0.529-1.593 0.761
Tumor resection 0.454 0.270-0.762 0.003*
Clinical stage 0.908 0.531-1.551 0.723
Treatment response 2.601 1.583-4.276 <0.001*
Recurrence and/or distant metastasis 4.172 1.700-10.240 0.002*angiogenesis mediate the aggressive tumor growth noted
in IL-6 expressing esophageal cancer, at least in part.
Radiotherapy is a well-established therapeutic modality
in oncology. It provides survival benefits in several cancer
types, including esophageal cancer. For esophageal SCC,
treatment response is an independent prognostic factor.
We demonstrated that positive IL-6 staining was signifi-
cantly associated with a lower response rate after treat-
ment in patients with esophageal SCC. As determined
using clonogenic assays and delayed tumor growth,
inhibition of IL-6 by transfection of an IL-6 silencing
vector increased radiosensitivity. Extensive DNA damage
caused by radiation and anti-cancer agents can result in
cell death or sensitivity to clinical treatment if left
unrepaired [36]. Phosphorylated H2AX is an indicator of
double-strand breaks, and its expression after irradiation
correlates with treatment sensitivity [37]. Our data
demonstrate that inhibition of IL-6 was associated with
increased radiation-induced DNA damage and increased
cell death. Moreover, the data from xenograft tumors
demonstrated that inhibition of IL-6 attenuated angiogen-
esis and decreased p-STAT3 activation after irradiation.
The expression of angiogenic factors is suggested to have
predictive value for treatment response and outcome in
patients with esophageal cancer [38,39]. Therefore, we
suggest activation of STAT3 signaling and angiogenesis
after irradiation was reported to be responsible for
resistance to treatment and tumor regrowth after irradi-
ation triggered by IL-6.
We further examined the predictive power of IL-6 for
prognosis in esophageal SCC. Besides a lower response toTable 7 Multivariate analysis to determine factors







IL-6 staining 7.622 3.580-16.226 <0.00
p-STAT3 staining 1.032 0.524-2.031 0.92
Clinical stage 0.828 0.409-1.677 0.60
Treatment response 2.327 1.314-4.120 0.004





Table 8 Multivariate analysis to determine factors







IL-6 staining 1.738 0.537-5.622 0.356
p-STAT3 staining 1.152 0.364-3.643 0.810
Clinical stage 0.860 0.332-2.232 0.757
Pathologic CR 1.883 0.518-6.842 0.336
Recurrence and/or distant metastasis 4.205 1.138-15.538 0.031*
Chen et al. Molecular Cancer 2013, 12:26 Page 11 of 12
http://www.molecular-cancer.com/content/12/1/26treatment, enhanced expression of IL-6 was significantly
associated with a higher clinical stage, a greater risk of
distant metastasis and shorter survival. In a multivariate
analysis, IL-6 retained predictive power for OS.
These findings indicate that IL-6-positive esophageal
cancer provides a suitable microenvironment for the
development of tumor growth and treatment resistance
mediated by induction of angiogenesis, enhancement of
cell mobility, and promotion of EMT. Our data support
the emerging notion that IL-6 and p-STAT3 are clinically
significant predictors, and suggest that IL-6 may represent
a suitable target for esophageal SCC treatment.
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